Diamantis, N., Banerji, U. (2016) Antibody-drug conjugates-an emerging class of cancer treatment. BRITISH JOURNAL OF CANCER, 114 (4). pp. 362-367. ISSN 0007-0920

Preview

Text 14853.pdf Download (422kB) | Preview

Abstract

Antibody-drug conjugates (ADCs) are an emerging novel class of anticancer treatment agents that combines the selectivity of targeted treatment with the cytotoxic potency of chemotherapy drugs. New linker technology associated with novel highly potent cytotoxic payloads has permitted the development of more effective and safe ADCs. In recent years, two ADCs have been licensed, T-DM1 and brentuximab vedotin, and are already establishing their place in cancer treatment. A plethora of ADCs are being investigated in phases I and II trials, emerging data of which appears promising. As we deepen our understanding of what makes a successful ADC, an increasing number of ADCs will likely become viable treatment options as single agents or in combination with chemotherapy. This review will present the philosophy underlying ADCs, their main characteristics and current research developments with a focus on ADCs in solid tumours.

Item Type:	Review Article
Authors (ICR Faculty only):	Banerji, udai
All Authors:	Diamantis, N., Banerji, U.
Additional Information:	ISI Document Delivery No.: DE2PW Times Cited: 0 Cited Reference Count: 45 Diamantis, Nikolaos Banerji, Udai Cancer Research UK; Experimental Cancer Medicine Centre; National Institute for Health Research Biomedical Research Centre; Hellenic Society of Medical Oncology (HESMO) The Drug Development Unit of the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research is supported in part by a programme grant from Cancer Research UK. Support is also provided by the Experimental Cancer Medicine Centre (programme grant) (to The ICR) and the National Institute for Health Research Biomedical Research Centre (jointly awarded to the RMH NHS Foundation Trust and The ICR). Scholarship awarded by the Hellenic Society of Medical Oncology (HESMO). 0 Nature publishing group London 1532-1827
Uncontrolled Keywords:	antibody-drug conjugate target antigen cytotoxic payload linker T-DM1 brentuximab vedotin MMAE resistance acute myeloid-leukemia large-cell lymphoma gemtuzumab ozogamicin trastuzumab emtansine brentuximab vedotin monoclonal-antibody antitumor-activity solid tumors stem-cells phase-ii Oncology
Research teams:	ICR divisions > Clinical Studies > Clinical Pharmacology – Adaptive Therapy ICR divisions > Cancer Therapeutics > Clinical Pharmacology – Adaptive Therapy
Depositing User:	Franziska Noessig
Date Deposited:	14 Mar 2016 18:57
Last Modified:	20 Mar 2018 14:37
URI:	http://publications.icr.ac.uk/id/eprint/14853

Actions (login required)

View Item